Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

101. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence (...) and resources for children's oral health Visit the Ad Council's children's oral health website Evidence Education About * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years

ADA Center for Evidence-Based Dentistry2013

102. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) and resources for children's oral health Visit the Ad Council's children's oral health website Evidence Education About * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years

ADA Center for Evidence-Based Dentistry2013

103. Calcitriol treatment is not effective in postmenopausal osteoporosis.

Calcitriol treatment is not effective in postmenopausal osteoporosis. Calcitriol treatment is not effec... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1987 ) Volume: 110 , Issue: 6 , Pages: 267-274 PubMed: Available from or Find this paper at: Abstract STUDY OBJECTIVE: To determine if calcitriol is an effective treatment in postmenopausal osteoporosis. DESIGN: Double-blind (...) and urine calcium values, but renal function was not worse than in the placebo group. CONCLUSIONS: Calcitriol is not an effective treatment for established postmenopausal osteoporosis. Related papers A Gürlek , M Bayraktar , O Gedik in Calcified Tissue International (1997) J F Aloia , A Vaswani , J K Yeh , K Ellis , S Yasumura , S H Cohn in Revue Medicale De Liege (2006) 1 reader Jean-Yves Reginster in BMJ British Medical Journal (2005) 33 readers A Caniggia , R Nuti , F Lore , G Martini , V Turchetti

Annals of Internal Medicine2013

105. Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing

Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate

Evidence-Based Medicine (Requires free registration)2013

106. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening

NHS Economic Evaluation Database.2013

107. Effectiveness of Teriparatide Therapy for Prevention of Fractures in Glucocorticoid-Induced Osteoporosis

Effectiveness of Teriparatide Therapy for Prevention of Fractures in Glucocorticoid-Induced Osteoporosis "Effectiveness of Teriparatide Therapy for Prevention of Fractures in G" by Tristan T. Stiles < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Second Advisor Eric Foote, PA-C, MS Third Advisor Mark Pedemonte, MD Rights . Abstract Background (...) : Glucocorticoids have a wide-range of beneficial effects for treating inflammatory, allergic, and immunologic conditions. However, glucocorticoid therapy can lead to increased bone resorption and reduced bone formation by inhibiting osteoblast proliferation. This bone deterioration leads to osteoporosis. When considering therapy for prevention of fractures in glucocorticoid-induced osteoporosis (GIO), teriparatide (recombinant human parathyroid hormone 1-34) is an anabolic agent that can be used to improve

Pacific University EBM Capstone Project2013

108. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems

FDA - Drug Approval Package2013

109. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. 23683600 2013 07 08 2013 07 30 2016 12 15 1474-547X 382 9886 2013 Jul 06 Lancet (London, England) Lancet Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. 50-6 10.1016/S0140-6736(13)60856-9 S0140-6736(13)60856-9 Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate (...) fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone. From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis into this randomised, controlled trial. Patients were assigned in a 1:1:1 ratio to receive 20 μg teriparatide daily, 60 mg denosumab every 6 months, or both. BMD was measured at 0, 3, 6, and 12 months. Women who completed at least one study visit

Lancet2013 Full Text: Link to full Text with Trip Pro

111. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference with dentistry's premier charitable organization Purchase ADA products (...) between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate Professor-Hygiene . Overview Systematic Review Conclusion While evidence suggests a relationship between osteoporosis and periodontitis, further studies are required to establish the nature of the relationship. Critical Summary Assessment This weak of observational studies does not provide adequate evidence to help identify patients at risk of osteoporosis based on periodontal findings. Evidence Quality Rating Limited

ADA Center for Evidence-Based Dentistry2012

112. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference with dentistry's premier charitable organization Take advantage of endorsed, discounted business products Purchase ADA products (...) between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate Professor-Hygiene . Overview Systematic Review Conclusion While evidence suggests a relationship between osteoporosis and periodontitis, further studies are required to establish the nature of the relationship. Critical Summary Assessment This weak of observational studies does not provide adequate evidence to help identify patients at risk of osteoporosis based on periodontal findings. Evidence Quality Rating Limited

ADA Center for Evidence-Based Dentistry2012

113. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Han SL, Wan SL CRD summary This review found that teriparatide was effective (...) in the treatment of postmenopausal osteoporosis, with reductions in risks of fracture and improvements in bone mineral density. Although the quality of the studies was generally low, the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy of teriparatide in reducing the risk of fractures and improving bone mineral density in postmenopausal women with osteoporosis. Searching PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and ISI Web of Knowledge were

DARE.2012

114. Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial

Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Vol 20. DTB: Vol 20, No 2. March - April 2012 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB: Vol 20, No 2. March - April 2012 DTB: Vol 20, No 2. March - April 2012 Content tools Share it Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Denosumab has shown efficacy vs placebo in the reduction of morphometric

Drug and Therapeutics Bulletin of Navarre (Spain)2012

115. Strontium ranelate (Protelos) - Treatment of osteoporosis in men at increased risk of fracture

Strontium ranelate (Protelos) - Treatment of osteoporosis in men at increased risk of fracture Published 08 October 2012 Statement of Advice strontium ranelate (Protelos®) 2g granules for oral suspension (No: 816/12) Servier Laboratories Limited 7 September 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation strontium ranelate (Protelos ®) is not recommended for use within NHS Scotland. Indication under review: Treatment of osteoporosis in men at increased

Scottish Medicines Consortium2012

116. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms

Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Evidence from six placebo-controlled randomized

Health Technology Assessment (HTA) Database.2012

117. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report

Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review

Health Technology Assessment (HTA) Database.2012

118. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines

Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Denosumab and zoledronic acid were shown to be safe

Health Technology Assessment (HTA) Database.2012

119. Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis.

Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create (...) File 1 selected item: 22986396 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 18;157(6):JC3-4. doi: 10.7326/0003-4819-157-6-201209180-02004. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. . Comment on [Int J Clin Pract. 2012] PMID: 22986396 DOI: Publication type Full

Annals of Internal Medicine2012

120. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of strategies of systematic screening for osteoporosis among postmenopausal women and medical treatments for those diagnosed positive. The authors

NHS Economic Evaluation Database.2012